Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.

about

Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.

Item

http://www.wikidata.org/entity/Q47780043

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.

@en

Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.

@nl

type

Item

label

Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.

@en

Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.

@nl

prefLabel

Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.

@en

Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.

@nl

P1476

Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.

@en

P2093

Alessandra Tedeschi

http://www.w3.org/2001/XMLSchema#string

Anna Maria Frustaci

http://www.w3.org/2001/XMLSchema#string

Maddalena Mazzucchelli

http://www.w3.org/2001/XMLSchema#string

Marco Montillo

http://www.w3.org/2001/XMLSchema#string

Marina Deodato

http://www.w3.org/2001/XMLSchema#string

Roberto Cairoli

http://www.w3.org/2001/XMLSchema#string

P2860

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.

Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Chemotherapy Significantly Improves Survival for Patients with T1c-T2N0M0 Medullary Breast Cancer: 3739 Cases From the National Cancer Data Base.

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

P31

scholarly article

P356

10.2217/FON-2017-0466

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29243946

http://www.w3.org/2001/XMLSchema#string

P921

lymphocyte